from the link
Skin ulcer at the injection site of COVID‐19 mRNA vaccine has never reported in the literature. This condition was clearly different from the delayed‐type local reaction known as COVID arm,
1 in that he experienced a painful erythematous lesion the next day, followed by development of an ulcer characterized by histological changes including thrombosis and vascular damage. However, it should be noted that he suffered from rheumatoid arthritis (RA), for which he was treated with iguratimod and salazosulfasalazine, and untreated polycythemia vera (PV). RA and PV are associated with complication of neutrophilic vasculitis and arterial/venous thrombosis, respectively.
2 ,
3 More importantly, the spike protein of SARS‐CoV‐2, which is encoded by the mRNA vaccine, binds to angiotensin‐converting enzyme 2, leading to pro‐thrombosis condition via the “adverse” angiotensin converting enzyme–angiotensin II–angiotensin type I, receptor axis.
4 Recently, cutaneous microthrombi were found in our previous case, who experienced morbilliform rash after administration of BNT162b2 mRNA vaccine.
5 In conclusion, attention should be paid to cutaneous thrombosis and vasculitis in those who have preceding diseases when given the COVID‐19 mRNA vaccines.
